BTIG analyst Ryan Zimmerman notes that the U.S. Preventive Services Task Force released a draft recommendation statement on screening for cervical cancer, recommending testing every three years for women 21-29 with cytology alone and every five years for women 30-65 with clinician- or patient-collected high-risk HPV primary screening. The net impact of these recommendations is that it does not encourage the use of cervical cancer screening in conjunction with HPV primary screening for the bulk of screening, but this is unchanged from the group’s prior recommendation in 2018, notes the analyst, who calls this “positive for HOLX on a relative basis as investors feared a more Draconian recommendation.” The firm maintains a Neutral rating on Hologic (HOLX) shares.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HOLX:
- Hologic Expands Board with Martin Madaus Appointment
- Hologic initiated with a Hold at Jefferies
- Hologic research showis Genius AI Detection performs across diverse populations
- Hologic Updates Executive Compensation Agreements for 2025
- Hologic price target raised to $89 from $86 at RBC Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
